Articles related to PEDIATRIC ENDOCRINOLOGY

The FDA approved inhaled insulin (Afrezza) for pediatric patients aged 6 and older with type 1 or type 2 diabetes, based on phase 3 trial data and long-term safety evidence from manufacturer-sponsored studies.

Pediatric patients who started automated insulin delivery within 6 months of type 1 diabetes diagnosis had a median HbA1c of 7.1% at 24 months versus 9.8% in non-users in a US multicenter retrospective cohort.

Children labeled metabolically healthy at obesity treatment initiation reached an 18-fold higher type 2 diabetes incidence by age 30 than general population peers in a 42,911-patient Swedish cohort.

“Families and health care professionals now have the option to consider a once-weekly growth hormone as treatment with 313 injection free days per year for their children 2.5 years and older with ISS, NS, and born SGA,” said Dr Aristides Maniatis, Founder, Rocky Mountain Pediatric Endocrinology.

The societal influences, including parental weight stigma, affect how parents perceive their child’s weight and respond to health care recommendations.

“We try to deescalate pharmacotherapy as soon as we can in children. How’s this going to affect puberty? How’s it going to affect growth? We don’t have those long-term data.”